Deerfield Management LEGN Position
Active7-Fund ConvergenceDeerfield Management increased their position in Legend Biotech Corporation (LEGN) in Q4 2025, holding $129.0M worth of shares across 5,932,000 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
LEGN is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 24.7% of float with 9.7 days to cover, indicating significant bearish positioning against Deerfield's long thesis.
About Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Full company profile →Short Interest
24.7%
9.7 days to cover
Deerfield Management LEGN Position History
Frequently Asked Questions
Does Deerfield Management own LEGN?
Yes. As of Q4 2025, Deerfield Management holds 5,932,000 shares of Legend Biotech Corporation (LEGN) valued at $129.0M. This data comes from their SEC 13F filing.
How many hedge funds own LEGN?
7 specialist biotech hedge funds currently hold LEGN, including RA Capital Management, Boxer Capital, Rock Springs Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy LEGN?
Deerfield Management's position in LEGN was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's LEGN position increasing or decreasing?
Deerfield Management increased their LEGN position in the most recent quarter, adding 2,969,662 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LEGNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →